14-Oct-2026
IDEXX Laboratories to Release 2026 Third Quarter Financial Results
Business Wire (Thu, 1-Oct 11:30 AM ET)
PRNewswire (Wed, 30-Sep 9:00 AM ET)
Business Wire (Thu, 17-Sep 3:00 AM ET)
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
Business Wire (Wed, 16-Sep 7:00 AM ET)
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Business Wire (Mon, 31-Aug 2:00 PM ET)
Business Wire (Tue, 11-Aug 7:00 AM ET)
IDEXX Laboratories Announces Second Quarter Results
Business Wire (Tue, 4-Aug 6:30 AM ET)
IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals
Business Wire (Tue, 28-Jul 7:00 AM ET)
IDEXX Laboratories Lifts 2025 Outlook as Diagnostics Drive Double-Digit Growth
Market Chameleon (Mon, 3-Nov 2:37 AM ET)
IDEXX Stock Rockets 26.5% After Earnings—Can History Offer Clues to What Happens Next?
Market Chameleon (Mon, 4-Aug 7:40 AM ET)
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Idexx Laboratories trades on the NASDAQ stock market under the symbol IDXX.
As of October 14, 2026, IDXX stock price climbed to $529.01 with 777,471 million shares trading.
IDXX has a beta of 0.67, meaning it tends to be less sensitive to market movements. IDXX has a correlation of 0.10 to the broad based SPY ETF.
IDXX has a market cap of $41.68 billion. This is considered a Large Cap stock.
Last quarter Idexx Laboratories reported $1 billion in Revenue and $4.27 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.33.
In the last 3 years, IDXX traded as high as $769.98 and as low as $356.14.
The top ETF exchange traded funds that IDXX belongs to (by Net Assets): VTI, VOO, VO, QQQ, IVV.
IDXX has underperformed the market in the last year with a return of -16.9%, while the SPY ETF gained +17.4%. In the last 3 month period, IDXX fell short of the market, returning -2.2%, while SPY returned +2.6%. However, in the most recent 2 weeks IDXX has outperformed the stock market by returning +1.3%, while SPY returned +0.9%.
IDXX support price is $512.18 and resistance is $528.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IDXX shares will trade within this expected range on the day.